Biotesys joins CERTANIA group
Leading nutritional cro enhances service offerings in nutraceutical, cosmetic, and medical device testing
Esslingen am Neckar/Munich, October 1, 2024—BioTeSys, a premier Contract Research Organization (CRO) specializing in the evaluation and testing of bioactive ingredients for nutraceuticals, cosmetics, and medical devices, proudly announces its integration into CERTANIA, a dynamic group focused on Testing, Inspection, and Certification (TIC) services. This strategic integration marks a significant milestone for BioTeSys, enhancing its ability to deliver comprehensive research and testing solutions across diverse sectors while acting as a "one-stop-shop" for its clients.
Founded in 1999 and headquartered in Esslingen am Neckar, Germany, BioTeSys has over 25 years of expertise in the nutritional and life sciences industries. The company offers a wide range of services, including advanced analytical methods such as HPLC and LC-MS, in vitro testing with single-cell cultures and co-cultures, and the planning and execution of clinical studies. With a strong focus on the evaluation of safety, efficacy, bioavailability, and the functional characteristics of bioactive ingredients, BioTeSys is recognized for its interdisciplinary expertise that provides customers with cohesive, reliable scientific data, saving both time and costs.
Through its integration into the CERTANIA group, BioTeSys can leverage extensive resources to further expand its service offerings, particularly in response to the growing demand for substantiating scientific evidence of product properties. This development is driven by increased market trends such as EFSA compliance, nutrivigilance, genotoxicity, and the analysis of botanicals (e.g., cannabinoids). This partnership strengthens BioTeSys's position in the nutraceutical, cosmetic, and medical device sectors by providing customers with enhanced decision-making security and budget compliance through an integrated service model.
Dr. Jürgen Bernhardt and Christiane Schön will continue to lead BioTeSys under the CERTANIA umbrella. "We are thrilled to join CERTANIA, a group that shares our commitment to excellence and innovation in research and testing," said Dr. Bernhardt, General Manager of BioTeSys. "This collaboration will allow us to benefit from CERTANIA’s robust resources and expertise, empowering us to deliver even more value to our clients."
Moritz Gruber, CEO and Managing Shareholder of CERTANIA, emphasized the strategic importance of acquiring BioTeSys. "The addition of BioTeSys significantly bolsters CERTANIA’s position in the nutraceutical and life sciences markets. Their expertise in bioactive ingredient analysis, in vitro testing, and clinical trials complements our existing service offerings. Together, we will unlock new synergies and drive growth."
CERTANIA’s acquisition of BioTeSys reflects the group’s commitment to expanding its capabilities in the nutritional and life sciences sectors while reinforcing its market presence in Germany and internationally. The integration is poised to drive innovation, improve supply chain efficiency, and foster significant growth within the CERTANIA group.
By becoming part of CERTANIA’s ecosystem, BioTeSys will retain its entrepreneurial freedom while benefiting from the group's vast network of resources and support, further enhancing its ability to serve its diverse, global customer base.
